Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects

被引:121
作者
Thomas, Remy [1 ]
Al-Khadairi, Ghaneya [1 ,2 ]
Decock, Julie [1 ,2 ]
机构
[1] Hamad Bin Khalifa Univ HBKU, Qatar Fdn QF, Canc Res Ctr, Qatar Biomed Res Inst QBRI, Doha, Qatar
[2] Hamad Bin Khalifa Univ HBKU, Qatar Fdn QF, Coll Hlth & Life Sci CHLS, Doha, Qatar
关键词
triple negative breast cancer; immune checkpoint blockade; predictive biomarkers; tumor mutational burden; tumor infiltrating lymphocytes; combination therapy; programmed death-1 (PD-1); programmed death ligand-1 (PD-L1); IMMUNOHISTOCHEMISTRY IHC ASSAYS; TUMOR-INFILTRATING LYMPHOCYTES; PHASE-III; PEMBROLIZUMAB; CELLS; ATEZOLIZUMAB; CHEMOTHERAPY; EXPRESSION; BIOMARKERS; LANDSCAPE;
D O I
10.3389/fonc.2020.600573
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient's own immune cells to kill tumors and revolutionizing cancer treatment in a variety of cancers. Although breast cancer was historically believed to be immunologically silent, treatment with immune checkpoint inhibitors has been shown to induce modest responses in metastatic breast cancer. Given the inherent heterogeneity of breast tumors, this raised the question whether certain breast tumors might benefit more from immune-based interventions and which cancer cell-intrinsic and/or microenvironmental factors define the likelihood of inducing a potent and durable anti-tumor immune response. In this review, we will focus on triple negative breast cancer as immunogenic breast cancer subtype, and specifically discuss the relevance of tumor mutational burden, the plethora and diversity of tumor infiltrating immune cells in addition to the immunoscore, the presence of immune checkpoint expression, and the microbiome in defining immune checkpoint blockade response. We will highlight the current immune checkpoint inhibitor treatment options, either as monotherapy or in combination with standard-of-care treatment modalities such as chemotherapy and targeted therapy. In addition, we will look into the potential of immunotherapy-based combination strategies using immune checkpoint inhibitors to enhance both innate and adaptive immune responses, or to establish a more immune favorable environment for cancer vaccines. Finally, the review will address the need for unambiguous predictive biomarkers as one of the main challenges of immune checkpoint blockade. To conclude, the potential of immune checkpoint blockade for triple negative breast cancer treatment could be enhanced by exploration of aforementioned factors and treatment strategies thereby providing promising future prospects.
引用
收藏
页数:17
相关论文
共 170 条
[1]   Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study [J].
Adams, S. ;
Loi, S. ;
Toppmeyer, D. ;
Cescon, D. W. ;
De Laurentiis, M. ;
Nanda, R. ;
Winer, E. P. ;
Mukai, H. ;
Tamura, K. ;
Armstrong, A. ;
Liu, M. C. ;
Iwata, H. ;
Ryvo, L. ;
Wimberger, P. ;
Rugo, H. S. ;
Tan, A. R. ;
Jia, L. ;
Ding, Y. ;
Karantza, V. ;
Schmid, P. .
ANNALS OF ONCOLOGY, 2019, 30 (03) :405-411
[2]   Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].
Adams, Sylvia ;
Diamond, Jennifer R. ;
Hamilton, Erika ;
Pohlmann, Paula R. ;
Tolaney, Sara M. ;
Chang, Ching-Wei ;
Zhang, Wei ;
Iizuka, Koho ;
Foster, Paul G. ;
Molinero, Luciana ;
Funke, Roel ;
Powderly, John .
JAMA ONCOLOGY, 2019, 5 (03) :334-342
[3]   Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. [J].
Adams, Sylvia ;
Loi, Sherene ;
Toppmeyer, Deborah ;
Cescon, David W. ;
De laurentiis, Michele ;
Nanda, Rita ;
Winer, Eric P. ;
Mukai, Hirofumi ;
Tamura, Kenji ;
Armstrong, Anne ;
Liu, Minetta C. ;
Iwata, Hiroji ;
Ryvo, Larisa ;
Wimberger, Pauline ;
Card, Deborah ;
Ding, Yu ;
Karantza, Vassiliki ;
Schmid, Peter .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4]   Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].
Adams, Sylvia ;
Gray, Robert J. ;
Demaria, Sandra ;
Goldstein, Lori ;
Perez, Edith A. ;
Shulman, Lawrence N. ;
Martino, Silvana ;
Wang, Molin ;
Jones, Vicky E. ;
Saphner, Thomas J. ;
Wolff, Antonio C. ;
Wood, William C. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Sparano, Joseph A. ;
Badve, Sunil S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+
[5]   Signatures of mutational processes in human cancer [J].
Alexandrov, Ludmil B. ;
Nik-Zainal, Serena ;
Wedge, David C. ;
Aparicio, Samuel A. J. R. ;
Behjati, Sam ;
Biankin, Andrew V. ;
Bignell, Graham R. ;
Bolli, Niccolo ;
Borg, Ake ;
Borresen-Dale, Anne-Lise ;
Boyault, Sandrine ;
Burkhardt, Birgit ;
Butler, Adam P. ;
Caldas, Carlos ;
Davies, Helen R. ;
Desmedt, Christine ;
Eils, Roland ;
Eyfjord, Jorunn Erla ;
Foekens, John A. ;
Greaves, Mel ;
Hosoda, Fumie ;
Hutter, Barbara ;
Ilicic, Tomislav ;
Imbeaud, Sandrine ;
Imielinsk, Marcin ;
Jaeger, Natalie ;
Jones, David T. W. ;
Jones, David ;
Knappskog, Stian ;
Kool, Marcel ;
Lakhani, Sunil R. ;
Lopez-Otin, Carlos ;
Martin, Sancha ;
Munshi, Nikhil C. ;
Nakamura, Hiromi ;
Northcott, Paul A. ;
Pajic, Marina ;
Papaemmanuil, Elli ;
Paradiso, Angelo ;
Pearson, John V. ;
Puente, Xose S. ;
Raine, Keiran ;
Ramakrishna, Manasa ;
Richardson, Andrea L. ;
Richter, Julia ;
Rosenstiel, Philip ;
Schlesner, Matthias ;
Schumacher, Ton N. ;
Span, Paul N. ;
Teague, Jon W. .
NATURE, 2013, 500 (7463) :415-+
[6]   Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].
Ali, H. R. ;
Provenzano, E. ;
Dawson, S-J ;
Blows, F. M. ;
Liu, B. ;
Shah, M. ;
Earl, H. M. ;
Poole, C. J. ;
Hiller, L. ;
Dunn, J. A. ;
Bowden, S. J. ;
Twelves, C. ;
Bartlett, J. M. S. ;
Mahmoud, S. M. A. ;
Rakha, E. ;
Ellis, I. O. ;
Liu, S. ;
Gao, D. ;
Nielsen, T. O. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543
[7]   Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study [J].
Ali, H. Raza ;
Chlon, Leon ;
Pharoah, Paul D. P. ;
Markowetz, Florian ;
Caldas, Carlos .
PLOS MEDICINE, 2016, 13 (12)
[8]   Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors [J].
Arora, Sanjeevani ;
Velichinskii, Rodion ;
Lesh, Randy W. ;
Ali, Usman ;
Kubiak, Michal ;
Bansal, Pranshu ;
Borghaei, Hossein ;
Edelman, Martin J. ;
Boumber, Yanis .
ADVANCES IN THERAPY, 2019, 36 (10) :2638-2678
[9]   PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy [J].
Asano, Takeru ;
Meguri, Yusuke ;
Yoshioka, Takanori ;
Kishi, Yuriko ;
Iwamoto, Miki ;
Nakamura, Makoto ;
Sando, Yasuhisa ;
Yagita, Hideo ;
Koreth, John ;
Kim, Haesook T. ;
Alyea, Edwin P. ;
Armand, Philippe ;
Cutler, Corey S. ;
Ho, Vincent T. ;
Antin, Joseph H. ;
Soiffer, Robert J. ;
Maeda, Yoshinobu ;
Tanimoto, Mitsune ;
Ritz, Jerome ;
Matsuoka, Ken-ichi .
BLOOD, 2017, 129 (15) :2186-2197
[10]   Distinct microbiological signatures associated with triple negative breast cancer [J].
Banerjee, Sagarika ;
Wei, Zhi ;
Tan, Fei ;
Peck, Kristen N. ;
Shih, Natalie ;
Feldman, Michael ;
Rebbeck, Timothy R. ;
Alwine, James C. ;
Robertson, Erle S. .
SCIENTIFIC REPORTS, 2015, 5